High-throughput structural genomics and proteomics: where are we now?

Since its initiation 3–4 years ago, the emerging field of structural genomics has faced many technical obstacles on the path to high-throughput protein structure determination. Although attrition in the gene-to-structure process remains high, much has been achieved and the first genome-scale studies are appearing in the literature. In terms of drug discovery, high-throughput structure determination is leading to increases in productivity, and to new approaches to hit identification.